Loading...
•
Dec 31, 2025
Amneal Q4 2025 Earnings Report
Amneal Q4 2025 Earnings Report
Key Takeaways
Amneal delivered a strong fourth quarter with an 11% revenue increase and a return to GAAP profitability. The performance was driven by significant growth in the Specialty and AvKARE segments, while the company met or exceeded all full-year 2025 guidance metrics.
Q4 2025 net revenue grew 11% year-over-year to $814 million, led by a 38% increase in Specialty revenue.
The company reported GAAP net income of $35 million for the quarter, compared to a net loss of $31 million in the prior year period.
Full-year 2025 net revenue exceeded $3 billion for the first time, marking the sixth consecutive year of execution and growth.
Amneal issued positive 2026 guidance, forecasting continued growth with net revenue expected between $3.05 billion and $3.15 billion.
Revenue by Segment
Forward Guidance
Amneal expects 2026 to be another year of growth across key financial metrics, supported by product launches and portfolio durability.
Positive Outlook
- 2026 Net revenue guidance of $3.05 billion - $3.15 billion
- Adjusted EBITDA expected between $720 million and $760 million
- Adjusted diluted EPS forecast of $0.93 - $1.03
- Affordable Medicines net revenue expected to grow 7% to 8%
- Operating cash flow projected between $325 million and $375 million
Challenges Ahead
- Specialty net revenue expected to be flat year-over-year
- Capital expenditures expected to increase to approximately $110 million
- Weighted-average diluted shares outstanding expected to increase to 330 million
- Timing of revenue for key products can impact segment performance
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...